DK2114990T3 - Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor - Google Patents

Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor

Info

Publication number
DK2114990T3
DK2114990T3 DK08726179.8T DK08726179T DK2114990T3 DK 2114990 T3 DK2114990 T3 DK 2114990T3 DK 08726179 T DK08726179 T DK 08726179T DK 2114990 T3 DK2114990 T3 DK 2114990T3
Authority
DK
Denmark
Prior art keywords
treatment
egfr
inhibitor
gene
response
Prior art date
Application number
DK08726179.8T
Other languages
English (en)
Other versions
DK2114990T5 (da
Inventor
Patrick J Muraca
Original Assignee
Nuclea Biomarkers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers Llc filed Critical Nuclea Biomarkers Llc
Application granted granted Critical
Publication of DK2114990T3 publication Critical patent/DK2114990T3/da
Publication of DK2114990T5 publication Critical patent/DK2114990T5/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08726179.8T 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor DK2114990T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90369407P 2007-02-27 2007-02-27
PCT/US2008/002602 WO2008106175A2 (en) 2007-02-27 2008-02-27 Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors

Publications (2)

Publication Number Publication Date
DK2114990T3 true DK2114990T3 (da) 2012-01-16
DK2114990T5 DK2114990T5 (da) 2012-05-07

Family

ID=39716322

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08726179.8T DK2114990T5 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
DK11008690.7T DK2413142T3 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11008690.7T DK2413142T3 (da) 2007-02-27 2008-02-27 Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor

Country Status (6)

Country Link
US (4) US20080206777A1 (da)
EP (2) EP2413142B1 (da)
AT (1) ATE531725T1 (da)
DK (2) DK2114990T5 (da)
ES (2) ES2376978T3 (da)
WO (1) WO2008106175A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814271A (pt) * 1997-12-12 2001-03-20 Digene Corp Determinação de doenças relacionadas com o vìrus do papiloma humano
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
AU2009238247B2 (en) * 2008-04-17 2014-12-11 Qiagen Gaithersburg, Inc. Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
TWI417389B (zh) 2008-10-27 2013-12-01 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
WO2010121238A2 (en) * 2009-04-17 2010-10-21 Translational Genomics Research Institute (Tgen) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
AU2010242867B2 (en) 2009-05-01 2016-05-12 Qiagen Gaithersburg, Inc. A non-target amplification method for detection of RNA splice-forms in a sample
JP5826752B2 (ja) 2009-09-14 2015-12-02 キアジェン ゲイサーズバーグ インコーポレイテッド 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法
ES2615728T3 (es) * 2010-01-29 2017-06-08 Qiagen Gaithersburg, Inc. Métodos y composiciones para una purificación y un análisis múltiple específico de secuencia de ácidos nucleicos
CA2787781A1 (en) 2010-01-29 2011-08-04 Qiagen Gaithersburg, Inc. Method of determining and confirming the presence of an hpv in a sample
WO2011106084A1 (en) * 2010-02-24 2011-09-01 Biodesix, Inc. Cancer patient selection for administration of therapeutic agents using mass spectral analysis
US9422593B2 (en) 2010-05-19 2016-08-23 Qiagen Gaithresburg, Inc Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
WO2012094059A2 (en) * 2010-11-10 2012-07-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing early stage non-small cell lung cancer
AU2012220575B2 (en) 2011-02-24 2017-01-12 Qiagen Gaithersburg, Inc. Materials and methods for detection of HPV nucleic acid
CN103926408A (zh) * 2014-04-30 2014-07-16 天津医科大学肿瘤医院 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN116098856B (zh) * 2023-01-16 2024-06-21 四川大学华西医院 光固化水凝胶复合核酸传递系统及治疗脊髓损伤的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US6482795B1 (en) * 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
EP1008650B1 (en) * 1997-07-03 2008-05-14 Asahi Kasei Pharma Corporation Novel mapk kinase
DE69934222T2 (de) 1998-02-25 2007-10-25 The United States Government As Represented By The Department Human Services Zellulare anordnungen für schnelle molekulare profilidentifizierung
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6582946B1 (en) * 2001-03-12 2003-06-24 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6727072B2 (en) * 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
EP1837025A3 (en) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
DK2114990T5 (da) 2012-05-07
ES2412432T3 (es) 2013-07-11
ATE531725T1 (de) 2011-11-15
EP2413142B1 (en) 2013-06-05
EP2413142A1 (en) 2012-02-01
EP2114990B9 (en) 2012-03-28
US20080206777A1 (en) 2008-08-28
DK2413142T3 (da) 2013-07-22
US20110189691A1 (en) 2011-08-04
US8088589B2 (en) 2012-01-03
WO2008106175A3 (en) 2008-11-20
US8900820B2 (en) 2014-12-02
EP2114990B1 (en) 2011-11-02
WO2008106175A2 (en) 2008-09-04
EP2114990A2 (en) 2009-11-11
EP2114990A4 (en) 2010-04-07
US8129125B2 (en) 2012-03-06
US20090263819A1 (en) 2009-10-22
US20120094311A1 (en) 2012-04-19
ES2376978T3 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
Carlberg et al. Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
JO3681B1 (ar) استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr
BR112013009376A2 (pt) métodos para determinar isótipos de anticorpos antifármacos
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
WO2007098444A3 (en) Methods for analysis of extracellular rna species
DK2903616T3 (da) Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
HK1208057A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
WO2013166186A8 (en) Method for determining complete response to anticancer therapy
BRPI0907637A8 (pt) biomarcadores p53
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
Shi et al. The plasma LncRNA acting as fingerprint in hilar cholangiocarcinoma
CY1119869T1 (el) Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras
WO2010030857A3 (en) Egfr inhibitor therapy responsiveness
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
Chintala et al. Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review
WO2010093450A3 (en) Pten phosphorylation-driven restistance to cancer treatment and altered prognosis
MX2014002144A (es) Metodo para predecir el beneficio clinico del tratamiento de los transtornos del desarrollo neurologico, neurologicos o neuropsiquiatricos.
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor